Brought to you by 
Five Prime partners again with Glaxo, this time in respiratory diseases
16 Apr 2021
Executive Summary
Five Prime Therapeutics Inc. (large-molecule candidates for cancer, respiratory, and autoimmune disorders) has granted GlaxoSmithKline PLC exclusive rights to its drug discovery tools--including the biotech’s library of functional human secreted proteins and transmembrane receptor proteins--to generate up to six respiratory disease programs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Five Prime partners again with Glaxo, this time in respiratory diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice